Business Context and Reporting Period
This Form 8-K is a current report filed by AcelRx Pharmaceuticals, Inc. (not TalpherA, Inc.) on March 27, 2018. The filing discloses the appointment of a new executive officer and associated compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and compensation terms.
Material Changes
The primary material change reported is the appointment of John Saia as General Counsel, effective April 16, 2018. Mr. Saia joins from McKesson Corporation, where he served for over 10 years in various legal and corporate secretary roles.
Compensation and Management Commentary
- Base Salary: $325,000 annually.
- Cash Bonus: Targeted at 35% of base salary, pro-rated for 2018, contingent on corporate and individual performance objectives.
- Equity Award: An option to purchase 145,000 shares of common stock under the 2011 Equity Incentive Plan. The exercise price will equal the closing sales price on the start date.
- Vesting Schedule: 25% vests on the first anniversary of the start date; the remaining 75% vests monthly over the subsequent 36 months (1/48th per month), subject to continuous service.
- Severance: Eligibility to participate in the Company's Amended and Restated Severance Benefit Plan.
Investor Verification Checklist
- Verify the exact closing stock price on April 16, 2018, to determine the exercise price of the 145,000 stock options.
- Review the full text of the Offer Letter (Exhibit 10.1) for specific performance metrics tied to the cash bonus.
- Confirm the terms of the Amended and Restated Severance Benefit Plan to understand potential exit costs.
- Monitor future filings for the formal approval of the equity award by the Compensation Committee.